Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arild Nesbakken

Showing results (51-60 of 84) with videos related to

Pageof 9
Sort By:
Diseases of the Colon and Rectum|February 9, 2008
Sentinel node mapping does not improve staging of lymph node metastasis in colonic cancerArne E Faerden, Ole H Sjo, Ole Sjo, et al.
Neoplasia (New York, N.Y.)|September 29, 2012
MiR-9, -31, and -182 deregulation promote proliferation and tumor cell survival in colon cancerLina Cekaite, Juha K Rantala, Jarle Bruun, et al.
Journal of Translational Medicine|September 9, 2021
Increased sensitivity to SMAC mimetic LCL161 identified by longitudinal ex vivo pharmacogenomics of recurrent, KRAS mutated rectal cancer liver metastasesKushtrim Kryeziu, Seyed H Moosavi, Christian H Bergsland, et al.
ESMO Open|July 20, 2019
Exploratory analyses of consensus molecular subtype-dependent associations of <i>TP53</i> mutations with immunomodulation and prognosis in colorectal cancerJørgen Smeby, Anita Sveen, Christian H Bergsland, et al.
Ebiomedicine|August 18, 2020
Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activityJørgen Smeby, Kushtrim Kryeziu, Kaja C G Berg, et al.
International Journal of Cancer|April 2, 2014
A novel transcript, VNN1-AB, as a biomarker for colorectal cancerMarthe Løvf, Torfinn Nome, Jarle Bruun, et al.
Molecular Oncology|December 16, 2020
Genomic and prognostic heterogeneity among RAS/BRAF<sup>V600E</sup> /TP53 co-mutated resectable colorectal liver metastasesKaja C G Berg, Tuva H Brunsell, Anita Sveen, et al.
Molecular Oncology|December 10, 2021
E-cadherin is a robust prognostic biomarker in colorectal cancer and low expression is associated with sensitivity to inhibitors of topoisomerase, aurora, and HSP90 in preclinical modelsJarle Bruun, Peter W Eide, Christian Holst Bergsland, et al.
Molecular Oncology|June 15, 2018
Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancerJarle Bruun, Anita Sveen, Rita Barros, et al.
NPJ Genomic Medicine|July 15, 2021
Metastatic heterogeneity of the consensus molecular subtypes of colorectal cancerPeter W Eide, Seyed H Moosavi, Ina A Eilertsen, et al.
Pageof 9

Showing results (51-60 of 84) with videos related to

Sort By:
Pageof 9
Diseases of the Colon and Rectum|February 9, 2008
Sentinel node mapping does not improve staging of lymph node metastasis in colonic cancerArne E Faerden, Ole H Sjo, Ole Sjo, et al.
Neoplasia (New York, N.Y.)|September 29, 2012
MiR-9, -31, and -182 deregulation promote proliferation and tumor cell survival in colon cancerLina Cekaite, Juha K Rantala, Jarle Bruun, et al.
Journal of Translational Medicine|September 9, 2021
Increased sensitivity to SMAC mimetic LCL161 identified by longitudinal ex vivo pharmacogenomics of recurrent, KRAS mutated rectal cancer liver metastasesKushtrim Kryeziu, Seyed H Moosavi, Christian H Bergsland, et al.
ESMO Open|July 20, 2019
Exploratory analyses of consensus molecular subtype-dependent associations of <i>TP53</i> mutations with immunomodulation and prognosis in colorectal cancerJørgen Smeby, Anita Sveen, Christian H Bergsland, et al.
Ebiomedicine|August 18, 2020
Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activityJørgen Smeby, Kushtrim Kryeziu, Kaja C G Berg, et al.
International Journal of Cancer|April 2, 2014
A novel transcript, VNN1-AB, as a biomarker for colorectal cancerMarthe Løvf, Torfinn Nome, Jarle Bruun, et al.
Molecular Oncology|December 16, 2020
Genomic and prognostic heterogeneity among RAS/BRAF<sup>V600E</sup> /TP53 co-mutated resectable colorectal liver metastasesKaja C G Berg, Tuva H Brunsell, Anita Sveen, et al.
Molecular Oncology|December 10, 2021
E-cadherin is a robust prognostic biomarker in colorectal cancer and low expression is associated with sensitivity to inhibitors of topoisomerase, aurora, and HSP90 in preclinical modelsJarle Bruun, Peter W Eide, Christian Holst Bergsland, et al.
Molecular Oncology|June 15, 2018
Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancerJarle Bruun, Anita Sveen, Rita Barros, et al.
NPJ Genomic Medicine|July 15, 2021
Metastatic heterogeneity of the consensus molecular subtypes of colorectal cancerPeter W Eide, Seyed H Moosavi, Ina A Eilertsen, et al.
Pageof 9